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Clinical PerspectiveWhat Is New?Contraindicated statin use in people living with HIV have declined between 2007 and 2014 because of less frequent prescriptions for HIV protease inhibitors.The decline in the use of contraindicated statins has diminished in the most recent years because of increasing prescriptions for antiretroviral regimens containing cobicistat.What Are the Clinical Implications?There is a need for increased awareness of statin drug interactions in people living with HIV to minimize avoidable adverse events.

Introduction {#jah33690-sec-0008}
============

The use of antiretroviral therapies (ART) has resulted in a decline in opportunistic infections and increased life expectancy among people living with HIV.[1](#jah33690-bib-0001){ref-type="ref"} As a result, adults with HIV are developing chronic illnesses associated with older age.[2](#jah33690-bib-0002){ref-type="ref"}, [3](#jah33690-bib-0003){ref-type="ref"} Cardiovascular disease (CVD) has emerged as a major cause of morbidity and mortality in people living with HIV.[3](#jah33690-bib-0003){ref-type="ref"}, [4](#jah33690-bib-0004){ref-type="ref"}, [5](#jah33690-bib-0005){ref-type="ref"}

Statin therapy is a mainstay of atherosclerotic CVD prevention.[6](#jah33690-bib-0006){ref-type="ref"}, [7](#jah33690-bib-0007){ref-type="ref"} The aging of people living with HIV and the high risk for CVD in this population may have resulted in an increased use of statin therapy in this population. Some statin types and dosages are contraindicated with medications commonly used to treat people living with HIV as they increase the risk for statin‐related adverse events, including muscle problems and acute kidney injury.[8](#jah33690-bib-0008){ref-type="ref"}, [9](#jah33690-bib-0009){ref-type="ref"} The risk for contraindicated statin use among adults with HIV may have changed over the past decade because of modifications in ART regimens.[10](#jah33690-bib-0010){ref-type="ref"}

The main aim of the current study was to analyze trends in the use of statins and contraindicated statin use among adults living with HIV who were treated with ART between 2007 and 2015. As a secondary aim, we identified factors associated with contraindicated statin use among adults with HIV in 2015. To accomplish these aims, we conducted a retrospective cohort study using data from the Marketscan database.

Methods {#jah33690-sec-0009}
=======

Study Population {#jah33690-sec-0010}
----------------

The Marketscan database contains administrative data from individuals enrolled in various employer‐sponsored healthcare plans and Medicare supplemental plans. We identified beneficiaries in the Marketscan database who had continuous inpatient, outpatient, and pharmacy insurance coverage for at least 1 full calendar year (ie, from January 1 through December 31) between 2007 and 2015 (hereinafter defined as the "assessment year"). We also required beneficiaries to have continuous inpatient, outpatient, and pharmacy insurance coverage from January 1 through December 31 of the year preceding the assessment year (hereinafter defined as the "baseline year") to identify baseline characteristics. We further restricted the analysis to beneficiaries who lived in the United States for the entire baseline and assessment years, were aged ≥19 years on January 1 of the assessment year and met the definition for HIV infection during the baseline year. HIV infection was defined by (1) ≥1 hospitalization with an *International Classification of Diseases, Ninth Revision* (*ICD‐9*) code of 042.x‐044.x or V08 in any discharge diagnosis position with ≥1 pharmacy claim for ART or (2) ≥2 pharmacy claims for ART on separate days. Table [S1](#jah33690-sup-0001){ref-type="supplementary-material"} shows the application of inclusion and exclusion criteria to identify the study population for the current analysis. The current analysis was approved by the Institutional Review Board at the University of Alabama at Birmingham, which waived the requirement to obtain informed consent. The Marketscan database used in the current study is available from Truven Health Analytics. Other study information is available from the corresponding author.

Beneficiary Characteristics {#jah33690-sec-0011}
---------------------------

Beneficiary characteristics analyzed as part of the current analysis included age on January 1 of the assessment year, sex, and region of residence defined using Marketscan beneficiary data. We used claims in the baseline year to determine comorbidities including a history of coronary heart disease (CHD), hypertension, diabetes mellitus, stroke, chronic kidney disease, and liver disease (Table [S2](#jah33690-sup-0001){ref-type="supplementary-material"}).

Use of Statins, ART, and Other Medications With Potential Contraindication With Statins {#jah33690-sec-0012}
---------------------------------------------------------------------------------------

Use of statins, ART, and other medications with potential contraindications with statins was determined using pharmacy claims during the assessment year. Statins analyzed as part of the current study included atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. ART included nucleoside reverse transcriptase inhibitors, non‐nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors, cobicistat, and integrase inhibitors. As described below, other medications with potential contraindications with statins analyzed as part of the current study included nefazodone, gemfibrozil, amiodarone, calcium channel blockers, antifungal medications, antibiotics, and hepatitis C virus protease inhibitors.

Contraindicated statin use was defined by a pharmacy fill for a statin type and dosage which should not be used because of an increased risk for statin‐related adverse events based on the medications filled in the preceding 90 days. Specific statin type and dosages which should not be used by individuals taking HIV protease inhibitors, cobicistat, hepatitis C protease inhibitors, antibiotics, antifungal medications, calcium channel blockers, amiodarone, gemfibrozil, and nefazodone are shown in Table [S3](#jah33690-sup-0001){ref-type="supplementary-material"}. These contraindications were defined in accordance with the guidelines for the management of adults living with HIV from the National Library of Medicine, National Institutes of Health.[11](#jah33690-bib-0011){ref-type="ref"}

Statistical Analysis {#jah33690-sec-0013}
--------------------

The analyses described below were conducted for each calendar year between 2007 and 2015, separately. We calculated baseline characteristics of beneficiaries included in the current analysis and the proportion who were taking ART and other medications with potential statin contraindications during the assessment year. We also calculated the proportion of beneficiaries taking a statin during the assessment year, overall and by statin type. Among beneficiaries taking a statin, we calculated the proportion taking ART and other medications with a potential statin contraindication. We also calculated the proportion of beneficiaries with contraindicated statin use. Using all contraindicated statin fills, we calculated the proportion attributable to nefazodone, gemfibrozil, amiodarone, calcium channel blockers, antifungal medications, antibiotics, hepatitis C virus protease inhibitors, cobicistat, and HIV protease inhibitors. We also calculated the proportion of all contraindicated statin fills by statin type and dosage.

We used Poisson regression models with robust variance estimators as described by Chen et al to calculate risk ratios and 95% confidence intervals for filling a contraindicated statin during the assessment year associated with calendar year and beneficiary characteristics.[12](#jah33690-bib-0012){ref-type="ref"} Characteristics that were investigated included age, sex, region of residence, and history of CHD, hypertension, diabetes mellitus, stroke, chronic kidney disease, and liver disease. An unadjusted model was conducted as was a model including all factors investigated simultaneously. All analyses were conducted using SAS v9.4 (SAS Institute Inc, Cary, NC).

Results {#jah33690-sec-0014}
=======

Characteristics of Beneficiaries With HIV {#jah33690-sec-0015}
-----------------------------------------

A total of 186 420 beneficiaries with HIV met the inclusion criteria for the current analysis. The percentage of beneficiaries with HIV who were aged ≥60 years increased from 9.4% in 2007 to 15.7% in 2015 (Table [1](#jah33690-tbl-0001){ref-type="table"}). In each calendar year, \>80% of beneficiaries were male and between 42% and 52% resided in the South region of the United States. Also, there was a progressive increase in the prevalence of CHD, hypertension, diabetes mellitus, chronic kidney disease, and liver disease between 2007 and 2015.

###### 

Baseline Characteristics of Beneficiaries With HIV Included in the Current Analysis

                           2007 (n=9928)   2008 (n=11 713)   2009 (n=19 868)   2010 (n=21 084)   2011 (n=24 781)   2012 (n=28 104)   2013 (n=24 892)   2014 (n=24 225)   2015 (n=21 825)
  ------------------------ --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  Age                                                                                                                                                                    
  \<50 y                   60.1            58.0              58.9              57.1              54.8              51.8              48.9              47.9              47.3
  50 to 59 y               30.5            31.6              31.1              32.1              33.4              34.8              36.0              37.0              37.1
  ≥60 y                    9.4             10.4              10.0              10.8              11.8              13.4              15.1              15.2              15.7
  Male                     84.8            84.6              84.9              84.6              85.0              84.3              84.4              83.3              83.2
  Region                                                                                                                                                                 
  Northeast                12.2            10.2              12.1              16.4              15.9              18.2              18.4              21.2              20.7
  North Central            13.5            13.4              15.4              16.7              15.0              14.4              13.0              13.4              12.8
  South                    51.8            50.3              47.0              42.3              44.0              43.8              42.4              44.8              47.2
  West                     22.3            25.7              24.1              24.4              24.2              22.7              25.4              19.3              19.2
  Unknown                  0.3             0.3               1.4               0.2               0.8               0.8               0.8               1.3               0.1
  Comorbidities                                                                                                                                                          
  Coronary heart disease   3.2             3.5               3.1               3.7               3.8               3.8               3.9               3.9               3.9
  Hypertension             30.6            32.1              31.2              32.1              33.6              34.5              35.1              35.4              35.7
  Diabetes mellitus        3.4             4.0               4.2               4.7               5.1               5.4               5.6               6.0               6.7
  Stroke                   0.4             0.5               0.4               0.5               0.5               0.5               0.5               0.5               0.6
  Chronic kidney disease   2.8             3.5               3.3               3.8               4.1               4.4               5.0               5.2               5.9
  Liver disease            2.9             3.4               3.7               4.2               4.3               4.3               4.3               4.5               4.9

Numbers in the table represent percentages.

Between 2007 and 2015, there was a progressive decline in the proportion of beneficiaries taking HIV protease inhibitors from 50.8% in 2007 to 25.5% in 2015 and fusion inhibitors from 2.2% to 0.1% (Table [2](#jah33690-tbl-0002){ref-type="table"}, top panel). The use of cobicistat increased from 0% before 2012 to 15.7% in 2015, while the use of integrase inhibitors increased from 2.0% in 2007 to 36.2% in 2015. In each year, the most commonly used non‐ART medications with potential contraindications with statins were calcium channel blockers, antifungal medications, and antibiotics (Table [2](#jah33690-tbl-0002){ref-type="table"}, bottom panel).

###### 

Use of ART and Other Medications With Potential Contraindications With Statins Among Beneficiaries With HIV

                                                                    2007 (n=9928)   2008 (n=11 713)   2009 (n=19 868)   2010 (n=21 084)   2011 (n=24 781)   2012 (n=28 104)   2013 (n=24 892)   2014 (n=24 225)   2015 (n=21 825)
  ----------------------------------------------------------------- --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  ART                                                                                                                                                                                                             
  Nucleoside reverse transcriptase inhibitors                       90.7            91.3              91.1              90.9              90.6              90.9              91.8              91.7              91.9
  Non‐nucleoside reverse transcriptase inhibitors                   50.8            54.1              55.1              55.6              56.3              57.7              57.1              54.0              48.5
  HIV protease inhibitors                                           50.8            48.3              45.6              42.6              40.3              37                34.5              30.8              25.5
  Fusion inhibitors                                                 2.2             1.2               0.5               0.3               0.2               0.2               0.2               0.1               0.1
  Entry inhibitors                                                  0.3             1.0               1.2               1.4               1.7               2.0               2.0               1.8               1.6
  Cobicistat                                                        0.0             0.0               0.0               0.0               0.0               1.2               5.0               9.6               15.7
  Integrase inhibitors                                              2.0             7.6               11.1              13.8              16.2              18.4              22.9              29.5              36.2
  Other medications with potential contraindications with statins                                                                                                                                                 
  Nefazodone                                                        0.1             0.1               0.1               0.1               0.1               0.1               0.1               0.1               0.0
  Gemfibrozil                                                       2.9             2.8               2.5               2.2               2.0               1.7               1.5               1.4               1.2
  Amiodarone                                                        0.1             0.1               0.1               0.1               0.2               0.1               0.1               0.1               0.1
  Calcium channel blockers                                          7.0             7.4               7.2               7.5               7.7               8.2               8.6               9.2               9.5
  Antifungal medications                                            7.6             6.7               6.2               5.7               5.7               5.4               5.1               4.9               5.0
  Antibiotics                                                       4.8             3.7               3.6               2.9               2.9               2.5               2.4               2.2               2.3
  Hepatitis C virus protease inhibitors                             0.0             0.0               0.0               0.0               0.1               0.2               0.1               0.2               0.0

Numbers in the table represent percentages over the total number of beneficiaries. ART indicates antiretroviral therapy.

Use of Statin Therapy {#jah33690-sec-0016}
---------------------

Statin use remained within 2 percentage points between 2007 and 2015 (Table [3](#jah33690-tbl-0003){ref-type="table"}). Atorvastatin was the statin most commonly used among beneficiaries with HIV during this time period, followed by pravastatin and rosuvastatin. Table [4](#jah33690-tbl-0004){ref-type="table"} shows the use of ART and other medications with potential contraindications with statins among beneficiaries with HIV taking statin therapy. Between 2007 and 2015, the use of HIV protease inhibitors and fusion inhibitors decreased while the use of cobicistat and integrase inhibitors increased among beneficiaries with HIV taking statin therapy. Calcium channel blockers, antifungal medications, gemfibrozil, and antibiotics were the most commonly used non‐ART medications with potential statin contraindications.

###### 

Percentage of Beneficiaries With HIV Taking Statin Therapy During the Assessment Year, Overall and by Statin Type

                 2007 (n=9928)   2008 (n=11 713)   2009 (n=19 868)   2010 (n=21 084)   2011 (n=24 781)   2012 (n=28 104)   2013 (n=24 892)   2014 (n=24 225)   2015 (n=21 825)
  -------------- --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  Any statin     24.6            25.3              25.6              25.4              25.5              26.0              26.4              25.5              24.7
  Atorvastatin   13.1            12.6              11.9              10.8              10.3              11.2              12.5              12.4              12.9
  Fluvastatin    0.2             0.2               0.2               0.1               0.1               0.1               0.1               0.1               0.1
  Lovastatin     0.6             0.5               0.4               0.4               0.4               0.4               0.3               0.3               0.3
  Pitavastatin   0.0             0.0               0.0               0.0               0.1               0.1               0.1               0.2               0.2
  Pravastatin    5.0             5.6               6.0               6.4               6.8               6.6               6.3               5.9               5.4
  Rosuvastatin   4.0             4.4               4.9               5.1               5.6               5.9               5.6               5.4               4.8
  Simvastatin    3.4             3.6               3.9               4.1               4.0               3.3               2.9               2.4               2.1

Numbers in the table represent column percentages. Within each calendar year, the sum of percentages for each statin type may be higher than the total percentage of beneficiaries taking statin therapy as some beneficiaries may have taken more than one statin type.

###### 

Use of ART and Other Medications With Potential Contraindications With Statins Among Beneficiaries With HIV Taking Statin Therapy

                                                                    2007 (n=2445)   2008 (n=2958)   2009 (n=5084)   2010 (n=5346)   2011 (n=6312)   2012 (n=7318)   2013 (n=6570)   2014 (n=6177)   2015 (n=5386)
  ----------------------------------------------------------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  ART                                                                                                                                                                                               
  Nucleoside reverse transcriptase inhibitors                       91.8            92.2            90.8            90.5            90.4            90.1            90.4            90.4            90.7
  Non‐nucleoside reverse transcriptase inhibitors                   54.4            58.1            58.0            58.3            59.0            60.0            58.8            56.3            52.2
  HIV protease inhibitors                                           54.6            51.8            48.6            46.0            44.3            40.6            38.9            36.0            32.0
  Fusion inhibitors                                                 2.9             1.5             0.7             0.4             0.3             0.2             0.2             0.2             0.1
  Entry inhibitors                                                  0.3             1.4             1.7             1.7             2.3             2.4             2.6             2.3             2.3
  Cobicistat                                                        0.0             0.0             0.0             0.0             0.0             0.8             3.8             6.7             12.3
  Integrase inhibitors                                              2.9             9.5             13.9            17.0            19.7            22.1            26.4            32.3            39.4
  Other medications with potential contraindications with statins                                                                                                                                   
  Nefazodone                                                        0.3             0.2             0.1             0.2             0.1             0.1             0.1             0.1             0.0
  Gemfibrozil                                                       5.3             5.2             4.5             3.8             3.2             3.1             2.6             2.4             2.4
  Amiodarone                                                        0.2             0.1             0.3             0.3             0.4             0.3             0.3             0.3             0.3
  Calcium channel blockers                                          11.2            11.8            11.3            11.9            12.0            12.6            13.0            15.1            15.9
  Antifungal medications                                            6.1             5.7             5.2             4.5             4.5             4.5             4.0             4.0             4.0
  Antibiotics                                                       4.9             3.4             4.1             2.8             3.0             2.6             2.1             2.1             2.4
  Hepatitis C virus protease inhibitors                             0.0             0.0             0.0             0.0             0.0             0.1             0.0             0.1             0.0

Numbers in the table represent percentages over the total number of beneficiaries taking statin therapy. ART indicates antiretroviral therapy.

Contraindicated Statin Use {#jah33690-sec-0017}
--------------------------

Among beneficiaries taking a statin, the percentage taking 1 with a contraindication declined from 16.3% in 2007 to 9.0% in 2014 and 9.8% in 2015 ([Figure](#jah33690-fig-0001){ref-type="fig"}). The lower use of contraindicated statins in 2015 versus 2007 was primarily the result of decreased use of HIV protease inhibitors, which accounted for 63.9% and 51.0% of all contraindicated statin fills in 2007 and 2015, respectively (Table [5](#jah33690-tbl-0005){ref-type="table"}). The higher use of contraindicated statins in 2015 versus 2014 was primarily attributable to cobicistat, which accounted for 20.6% of all contraindicated statin fills in 2015.

![Contraindicated statin use and relative contribution of ART and other medications among beneficiaries with HIV taking statin therapy. The relative contribution of ART and other medications to contraindicated statin use was calculated using percentages shown in Table [5](#jah33690-tbl-0005){ref-type="table"}.](JAH3-7-e010345-g001){#jah33690-fig-0001}

###### 

Contraindicated Statin Fills in the Assessment Year Attributed to ART and Other Medications With Potential Contraindications With Statins

                                                                    2007   2008   2009   2010   2011   2012   2013   2014   2015
  ----------------------------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  Contraindicated statin fills, n                                   1736   1944   3465   3255   3510   3666   2940   2573   2440
  ART                                                                                                                       
  HIV protease inhibitors                                           63.9   60.2   63.2   60.6   62.5   63.4   59.2   57.2   51.0
  Cobicistat                                                        0.0    0.0    0.0    0.0    0.0    0.4    6.5    13.1   20.6
  Other medications with potential contraindications with statins                                                           
  Nefazodone                                                        0.1    0.1    0.0    0.1    0.0    0.0    0.0    0.0    0.0
  Gemfibrozil                                                       28.7   33.2   28.1   29.8   27.8   28.9   28.8   26.0   22.6
  Amiodarone                                                        0.0    0.0    0.4    0.2    0.0    0.2    0.2    0.0    0.0
  Calcium channel blockers                                          4.2    3.9    6.1    7.5    7.8    5.8    3.8    2.6    4.5
  Antifungal medications                                            0.9    0.3    0.3    0.4    0.3    0.2    0.2    0.1    0.0
  Antibiotics                                                       2.2    2.2    1.9    1.5    1.5    1.1    1.4    1.1    1.3
  Hepatitis C virus protease inhibitors                             0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0

With the exception of the first row (contraindicated statin fills, n), the numbers in the table represent column percentages over the total number of contraindicated statin fills (ie, beneficiaries may have multiple contraindicated statin fills in the assessment year). ART indicates antiretroviral therapy.

Between 2007 and 2010, simvastatin represented about a third of all contraindicated statin fills and this percentage declined to 13.5% in 2015 (Table [6](#jah33690-tbl-0006){ref-type="table"}). The proportion of contraindicated statin fills that were associated with fluvastatin also declined between 2007 and 2015, while those for atorvastatin and rosuvastatin increased. In 2015, atorvastatin and rosuvastatin fills represented 58.0% and 20.0% of all contraindicated statin fills, respectively.

###### 

Distribution of Contraindicated Statin Fills in the Assessment Year by Statin Type and Dosage

                                    2007   2008   2009   2010   2011   2012   2013   2014   2015
  --------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------
  Contraindicated statin fills, n   1736   1944   3465   3255   3510   3666   2940   2573   2440
  Atorvastatin                                                                              
  Any dose                          37.3   40.2   40.4   37.4   39.1   41.9   52.5   56.7   58.0
  10 mg                             3.9    4.6    3.7    2.7    3.3    3.4    3.9    2.5    2.7
  20 mg                             5.9    6.1    4.1    3.9    3.2    2.8    5.6    5.8    5.0
  40 mg                             21.4   24.7   26.1   21.9   21.7   26.1   31.8   39.1   40.0
  80 mg                             6.1    4.8    6.5    8.9    10.9   9.6    11.3   9.4    10.3
  Fluvastatin                                                                               
  Any dose                          1.2    0.7    0.4    0.2    0.1    0.2    0.0    0.2    0.2
  20 mg                             0.7    0.6    0.3    0.0    0.0    0.0    0.0    0.0    0.0
  80 mg                             0.5    0.2    0.1    0.2    0.1    0.2    0.0    0.2    0.2
  Lovastatin                                                                                
  Any dose                          2.8    2.1    2.5    1.2    2.3    1.5    2.4    2.3    2.3
  10 mg                             0.0    0.1    0.0    0.1    0.1    0.1    0.5    0.8    0.7
  20 mg                             2.0    1.1    1.6    0.3    0.7    0.5    1.1    1.1    1.3
  40 mg                             0.8    0.8    0.8    0.8    1.5    0.9    0.9    0.5    0.3
  Pitavastatin                                                                              
  Any dose                          0.0    0.0    0.0    0.0    0.0    0.2    0.3    0.3    0.7
  1 mg                              0.0    0.0    0.0    0.0    0.0    0.1    0.1    0.0    0.0
  2 mg                              0.0    0.0    0.0    0.0    0.0    0.0    0.1    0.3    0.2
  4 mg                              0.0    0.0    0.0    0.0    0.0    0.1    0.1    0.0    0.5
  Pravastatin                                                                               
  Any dose                          8.2    9.8    8.7    8.7    9.3    9.8    8.8    6.8    5.2
  10 mg                             0.5    0.1    0.4    0.3    1.0    1.1    0.6    0.3    0.1
  20 mg                             1.3    2.5    2.1    1.8    2.7    1.7    1.9    1.9    1.5
  40 mg                             4.7    4.8    5.0    4.9    3.4    4.3    4.3    3.0    2.3
  80 mg                             1.7    2.5    1.3    1.7    2.2    2.7    2.1    1.6    1.4
  Rosuvastatin                                                                              
  Any dose                          17.1   17.3   16.9   21.0   20.5   24.8   20.3   18.6   20.0
  5 mg                              0.2    0.4    0.6    0.9    0.9    1.0    0.8    1.3    1.5
  10 mg                             0.9    1.0    1.2    1.5    1.4    1.9    2.2    1.5    1.8
  20 mg                             12.8   11.9   11.6   14.2   14.4   15.9   11.9   11.0   11.1
  40 mg                             3.2    4.0    3.5    4.5    3.9    6.1    5.5    4.9    5.7
  Simvastatin                                                                               
  Any dose                          33.5   29.9   31.1   31.4   28.6   21.6   15.7   15.0   13.5
  5 mg                              0.2    0.5    0.3    0.6    0.3    0.2    0.1    0.2    0.1
  10 mg                             3.8    2.4    1.3    2.0    2.0    0.8    1.2    1.2    1.2
  20 mg                             13.8   11.5   10.9   9.4    8.5    6.8    6.5    5.9    3.6
  40 mg                             12.2   10.3   12.1   12.1   13.3   12.2   7.0    7.5    8.2
  80 mg                             3.5    5.3    6.5    7.3    4.5    1.6    0.9    0.2    0.4

With the exception of the first row (contraindicated statin fills, n), the numbers in the table represent column percentages over the total number of contraindicated statin fills (ie, beneficiaries may have multiple contraindicated statin fills in the assessment year).

Factors Associated With Contraindicated Statin Use Among Beneficiaries With HIV Taking Statin Therapy {#jah33690-sec-0018}
-----------------------------------------------------------------------------------------------------

Among beneficiaries with HIV taking statin therapy, contraindications declined between 2007 and 2015, and this association remained statistically significant after multivariable adjustment (Table [7](#jah33690-tbl-0007){ref-type="table"}). Older age, male sex, living in the West, North Central, and South versus the Northeast region of the United States, and having a history of CHD, hypertension, diabetes mellitus, and chronic kidney disease were associated with an increased risk for taking a contraindicated statin among beneficiaries with HIV taking statin therapy in unadjusted analyses. With the exception of chronic kidney disease, these factors remained associated with an increased risk for contraindicated statin use after multivariable adjustment.

###### 

Risk Ratios (95% Confidence Intervals) for a Contraindicated Statin Use During the Assessment Period Associated With Calendar Year and Beneficiary Characteristics Among Beneficiaries With HIV Taking Statin Therapy

                           Beneficiaries With HIV Taking Statin Therapy (n=47 596)   
  ------------------------ --------------------------------------------------------- -------------------
  Age                                                                                
  \<50 y                   1 (reference)                                             1 (reference)
  50 to 59 y               1.24 (1.13, 1.35)                                         1.23 (1.12, 1.35)
  ≥60 y                    1.23 (1.10, 1.37)                                         1.18 (1.04, 1.33)
  Male                     1.30 (1.13, 1.49)                                         1.26 (1.10, 1.45)
  Year                                                                               
  2007                     1 (reference)                                             1 (reference)
  2008                     0.94 (0.87, 1.03)                                         0.92 (0.85, 1.01)
  2009                     0.89 (0.81, 0.98)                                         0.89 (0.81, 0.98)
  2010                     0.83 (0.75, 0.92)                                         0.82 (0.74, 0.91)
  2011                     0.73 (0.66, 0.82)                                         0.71 (0.64, 0.79)
  2012                     0.62 (0.56, 0.69)                                         0.60 (0.54, 0.67)
  2013                     0.60 (0.54, 0.67)                                         0.57 (0.51, 0.64)
  2014                     0.55 (0.49, 0.62)                                         0.53 (0.47, 0.59)
  2015                     0.60 (0.54, 0.68)                                         0.57 (0.50, 0.64)
  Region                                                                             
  Northeast                1 (reference)                                             1 (reference)
  North Central            1.28 (1.10, 1.50)                                         1.21 (1.03, 1.41)
  South                    1.22 (1.07, 1.39)                                         1.18 (1.04, 1.35)
  West                     1.36 (1.18, 1.56)                                         1.29 (1.12, 1.48)
  Unknown                  1.04 (0.67, 1.61)                                         1.04 (0.67, 1.60)
  Comorbidities                                                                      
  Coronary heart disease   1.49 (1.34, 1.65)                                         1.34 (1.20, 1.50)
  Hypertension             1.28 (1.18, 1.40)                                         1.16 (1.06, 1.27)
  Diabetes mellitus        1.43 (1.29, 1.58)                                         1.38 (1.24, 1.54)
  Stroke                   1.13 (0.88, 1.45)                                         1.01 (0.78, 1.30)
  Chronic kidney disease   1.28 (1.14, 1.44)                                         1.12 (0.99, 1.27)
  Liver disease            0.88 (0.70, 1.10)                                         0.82 (0.66, 1.03)

The multivariable adjusted model includes adjustment for all variables in the table simultaneously.

Discussion {#jah33690-sec-0019}
==========

In the current analysis, about 25% of beneficiaries living with HIV were taking a statin and this percentage did not change substantially between 2007 and 2015. The proportion of patients with HIV taking contraindicated statins declined between 2007 and 2014, primarily as the result of the lower use of protease inhibitors. This decline was partially counteracted by the increased use of cobicistat after 2012. As a consequence of the increased use of cobicistat, the proportion of HIV beneficiaries taking contraindicated statins did not continue to decrease through 2015. Factors associated with contraindicated statin use included older age, male sex, living in the North Central, South, and West versus the Northeast region of the United States, and having a history of CHD, hypertension, and diabetes mellitus.

Statins are considered the first‐line therapy to lower CVD risk in HIV‐infected adults by the National Lipid Association because of their cholesterol‐lowering and anti‐inflammatory properties.[13](#jah33690-bib-0013){ref-type="ref"} Previous studies suggest that the use of statin therapy is low among HIV‐infected adults.[14](#jah33690-bib-0014){ref-type="ref"}, [15](#jah33690-bib-0015){ref-type="ref"} The current analysis expands on prior studies by showing that the use of statin therapy has not increased between 2007 and 2015 among beneficiaries with HIV. This finding is concerning as factors associated with a higher CVD risk, including older age, history of CHD, diabetes mellitus, and chronic kidney disease have increased among beneficiaries with HIV over this time period.[16](#jah33690-bib-0016){ref-type="ref"}, [17](#jah33690-bib-0017){ref-type="ref"}, [18](#jah33690-bib-0018){ref-type="ref"} These results highlight the need for increasing the appropriate use of statins among patients with HIV. Additionally, studies are needed to identify the barriers preventing statin use among people living with HIV.

In the current analysis, the use of contraindicated statins among beneficiaries with HIV declined between 2007 and 2014. This decline was mainly the result of the lower use of protease inhibitors. Results from the current analysis also suggest that cobicistat, a pharmacokinetic booster/enhancer, has counteracted some of the decline in contraindicated statin use. Cobicistat is a potent inhibitor of the cytochrome P‐450 3A4 (CYP3A4) and increases the concentration of statins metabolized through this enzyme system.[19](#jah33690-bib-0019){ref-type="ref"}, [20](#jah33690-bib-0020){ref-type="ref"} Cobicistat may also increase the serum concentration of statins by inhibiting the permeability glycoprotein, the breast cancer resistance protein, and the organic anion‐transporting polypeptides 1B1 and 1B3.[19](#jah33690-bib-0019){ref-type="ref"}, [20](#jah33690-bib-0020){ref-type="ref"} Cobicistat was initially approved by the Food and Drug Administration in a fixed‐dose combination with elvitegravir, emtricitabine, and tenofovir disoproxil in August 2012.[21](#jah33690-bib-0021){ref-type="ref"} After its approval, the use of cobicistat increased substantially among adults with HIV.[10](#jah33690-bib-0010){ref-type="ref"} In the current analysis, the use of contraindicated statins attributable to taking cobicistat increased substantially between 2012 and 2015. This finding suggests a lack of awareness of contraindications for statin therapy associated with cobicistat. Increasing physicians' awareness and implementing electronic prescription systems with drug‐drug interaction checks may reduce the contraindicated use of statins attributed to cobicistat among HIV patients.[22](#jah33690-bib-0022){ref-type="ref"}, [23](#jah33690-bib-0023){ref-type="ref"} Patients with HIV taking cobicistat who initiate statin therapy should be prescribed atorvastatin or rosuvastatin at the lowest dosages and these medications should be titrated with close monitoring for adverse reactions.[8](#jah33690-bib-0008){ref-type="ref"}, [24](#jah33690-bib-0024){ref-type="ref"}

Non‐ART therapies commonly prescribed in adults with HIV also contribute to the use of contraindicated statins. In the current analysis, gemfibrozil accounted for 22.6% of contraindicated statin use in 2015. Elevated triglycerides levels are common among HIV patients, particularly in those taking protease inhibitors.[25](#jah33690-bib-0025){ref-type="ref"} In HIV patients requiring triglyceride‐lowering therapy, fenofibrate and omega‐3 fatty acids should be preferred over gemfibrozil given their lower risk for rhabdomyolysis when combined with statins.[26](#jah33690-bib-0026){ref-type="ref"}, [27](#jah33690-bib-0027){ref-type="ref"} In the current analysis, the use of calcium channel blockers increased between 2007 and 2015, presumably because of the higher prevalence of hypertension in more recent years. In 2015, calcium channel blockers accounted for 4.5% of contraindicated statin use. Among HIV patients with hypertension taking statins, the use of antihypertensive medication classes other than calcium channel blockers should be considered. The 2017 American College of Cardiology/American Heart Association blood pressure guideline recommends thiazide diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers in addition to calcium channel blockers for adults initiating antihypertensive medication.[28](#jah33690-bib-0028){ref-type="ref"} Future surveillance on the use of calcium channel blockers and statins among HIV patients is warranted as this population is aging.

Simvastatin and lovastatin should be avoided in HIV‐infected adults as these medications are contraindicated with several ARTs including protease inhibitors.[9](#jah33690-bib-0009){ref-type="ref"}, [11](#jah33690-bib-0011){ref-type="ref"}, [13](#jah33690-bib-0013){ref-type="ref"} Use of atorvastatin, rosuvastatin, or pitavastatin is preferable in HIV patients, although dosing adjustments may be required.[9](#jah33690-bib-0009){ref-type="ref"}, [13](#jah33690-bib-0013){ref-type="ref"} In the current analysis, there was a decline in the proportion of contraindicated statin attributable to simvastatin, particularly after 2010. Several factors could have contributed to this decline in the use of simvastatin, including increasing awareness about the contraindication with ART, increased concerns about adverse muscle events associated with this medication,[29](#jah33690-bib-0029){ref-type="ref"}, [30](#jah33690-bib-0030){ref-type="ref"} and the availability of low‐cost atorvastatin after becoming generic in 2011.[31](#jah33690-bib-0031){ref-type="ref"} In 2015, 58.0% and 20.0% of contraindicated statin use was attributable to atorvastatin and rosuvastatin, respectively. These results suggest a lack of awareness on the need for dosing adjustment when using atorvastatin and rosuvastatin in people with HIV.

The use of contraindicated statins was higher in subgroups with high CVD risk, including older patients, men, and those with CHD, hypertension, or diabetes mellitus. This finding may be explained by the use of high‐intensity statin dosages in these groups. The use of contraindicated statins was also higher in beneficiaries with HIV living in the South and West versus the Northeast US region. Given the high proportion of HIV‐patients living in the South and West regions of the United States,[32](#jah33690-bib-0032){ref-type="ref"} increased awareness of contraindicated statins by healthcare professionals who care for HIV patients in these regions is warranted.

We analyzed trends and factors associated with contraindicated use of statins as this increases the risk for adverse events associated with this medication.[9](#jah33690-bib-0009){ref-type="ref"}, [13](#jah33690-bib-0013){ref-type="ref"} Some medications commonly used among HIV patients may reduce the efficacy of statin therapy.[9](#jah33690-bib-0009){ref-type="ref"} Non‐nucleoside reverse transcriptase inhibitors may reduce serum concentrations of statins metabolized through the CYP3A4 enzyme system.[9](#jah33690-bib-0009){ref-type="ref"} Because non‐nucleoside reverse transcriptase inhibitors do not increase the risk for statin‐related adverse events, these medications were not considered a contraindication in the current analysis. However, clinicians should be aware of possible drug‐drug interactions when prescribing statins in HIV‐patients taking non‐nucleoside reverse transcriptase inhibitors.[8](#jah33690-bib-0008){ref-type="ref"}

Strengths of the current study include the availability of data on ART and statin use in a large cohort of HIV patients from all regions of the United States. The pharmacy data we used included medications and dosages. The current study has several known and potential limitations. Misclassification of the use of statins, ART, and other medications with contraindications with statins is possible given that we relied on pharmacy fill data. These data indicate that beneficiaries filled a prescription but not whether they took it. Also, using administrative claims data may result in misclassification of baseline characteristics and HIV infection status if diagnosis codes for these conditions are not used or incorrectly used. We lacked data on estimated glomerular filtration rate, which prevented us from determining additional contraindications with specific statin doses resulting from renal impairment. Also, we did not have data on socioeconomic status and race/ethnicity. These data are not available in Marketscan.

Conclusion {#jah33690-sec-0020}
==========

In conclusion, in this large population with health insurance, the percentage of beneficiaries living with HIV that was taking a statin did not increase between 2007 and 2015 despite aging and a higher prevalence of CHD, hypertension, diabetes mellitus, and chronic kidney disease. The use of contraindicated statins declined between 2007 and 2014, primarily because of lower use of protease inhibitors. However, the increased use of cobicistat attenuated this decline. The current study supports the need to increase the appropriate use of statins among people living with HIV consistent with clinical practice guidelines. Also, clinicians should be vigilant in prescribing statin types and dosages with no or minimal contraindications among adults living with HIV.
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